Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSDVKK)

Drug Name

PF-07059013 Drug Info

Synonyms

PF-07059013; 6-{(1S)-1-[(2-amino-6-fluoroquinolin-3-yl)oxy]ethyl}-5-(1H-pyrazol-1-yl)pyridin-2(1H)-one; 2435610-93-6; 6-((1S)-1-((2-Amino-6-fluoroquinolin-3-yl)oxy)ethyl)-5-(1H-pyrazol-1-yl)pyridin-2(1H)-one; FXK42BP3GL; CHEMBL4650304; SCHEMBL21988630; GTPL12786; BDBM50565929; compound 23 [PMID: 33356244]; HY-139293; CS-0188516; PF07059013; 6-[(1S)-1-(2-amino-6-fluoroquinolin-3-yl)oxyethyl]-5-pyrazol-1-yl-1H-pyridin-2-one; (S)-6-(1-((2-Amino-6-fluoroquinolin-3-yl)oxy)ethyl)-5-(1H-pyrazol-1-yl)pyridin-2(1H)-one; 2(1H)-Pyridinone, 6-((1S)-1-((2-amino-6-fluoro-3-quinolinyl)oxy)ethyl)-5-(1H-pyrazol-1-yl)-; VUD

Indication

Disease Entry	ICD 11	Status	REF
Sickle-cell disorder	3A51	Phase 1	[1]

Cross-matching ID

PubChem CID: 146591762
TTD Drug ID: DMSDVKK

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Hemoglobin subunit beta (HBB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LentiGlobin	DMSCGM8	Beta thalassemia	3A50.2	Phase 3	[3]
OTL-300	DMYGK1D	Beta thalassemia	3A50.2	Phase 1/2	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hemoglobin subunit beta (HBB)	TTM6HK1	HBB_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04323124) A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE DOSE ESCALATION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-07059013 AND OPEN-LABEL ASSESSMENT OF FOOD AND FORMULATION ON PHARMACOKINETICS OF PF-07059013 IN HEALTHY ADULT PARTICIPANTS. U.S.National Institutes of Health.
2	PF-07059013: A non-covalent hemoglobin modulator favorably impacts disease state in a mouse model of sickle cell disease. Am J Hematol. 2021 Aug 1;96(8):E272-E275.
3	Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of beta-thalassemia and sickle cell disease. Curr Gene Ther. 2015;15(1):64-81.
4	Clinical pipeline report, company report or official report of Orchard Therapeutics.